Merck (MRK) shares have been stuck in neutral for some time as the company’s growth rates haven’t been enough to spur buyer interest. Of course, Merck isn’t alone in this as the mega-pharmas all have problems with growth, but it doesn’t make it any less painful. One thing that Merck has been struggling with in addition to its own growth rates is forex translation given that it gets a significant portion of its revenue outside the US. That has caused a struggle for Merck when it comes to growth because its uphill battle was a lot steeper when currency was factored in. But the weak dollar has afforded Merck a rather sizable opportunity to see some additional growth as the greenback reverses course and goes lower.
We’ll begin with a look at the dollar this year as represented by the UUP and suffice it to say that it isn’t pretty.
